17-Allylaminogeldanamycin - Amerigo Scientific

- Overview
  - 17-AAG is the first clinically tested hsp90 inhibitor that exhibits antitumor activity. Its antitumor effects are documented in vivo for various animal models, including erbB2-dependent breast cancer, prostate cancer models, and melanoma.
    
    Please contact us at for specific academic pricing.
- Properties
  - Categories
    
    Protein Interactions
    
    Alternative Name
    
    17-Demethoxy-17-(2-propenylamino)geldanamycin; Telatinib; Tanespimycin; 17-AAG
    
    CAS Number
    
    75747-14-7
    
    Molecular Formula
    
    C31H43N3O8
    
    Molecular Weight
    
    585.69 g/mol
    
    MDL Number
    
    MFCD04973892
    
    Note
    
    There is no hazardous surcharge associated with this product.
    There is no special packaging charge associated with this product.
    
    * For research use only. Not for human or veterinary use
- Reference
  - Smith-Jones (2007). Imaging. Comprehensive Medicinal Chemistry II, 659-677.
    Sausville (2008). Heat shock protein-90 directed therapeutics and target validation. Cancer Drug Design and Discovery, 336-350.